At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL
In Brief
A Phase 2 clinical trial evaluating Dinaciclib, Laboratory Biomarker Analysis, and 2 other interventions for Chronic Lymphocytic Leukemia and 3 related conditions. Completed, enrolled 36 participants across 1 site.
Detailed Summary
This phase I/II trial studies the side effects and the best dose of ofatumumab and dinaciclib and to see how well they work in treating patients with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, or B-cell prolymphocytic leukemia. Monoclonal antibodies, such as ofatumumab, can find cancer cells and help kill them. Dinaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving ofatumumab together with dinaciclib may kill more cancer cells.
Study Details
Timeline
Interventions
Given IV
Correlative studies
Given IV
Correlative studies